Senseonics Holdings Inc (NYSEAMERICAN:SENS) was down 5.7% during trading on Thursday . The company traded as low as $2.00 and last traded at $2.00. Approximately 1,563,542 shares were traded during mid-day trading, a decline of 7% from the average daily volume of 1,679,184 shares. The stock had previously closed at $2.12.

A number of research firms have weighed in on SENS. Piper Jaffray Companies began coverage on shares of Senseonics in a research note on Tuesday, January 29th. They issued a “neutral” rating on the stock. Zacks Investment Research downgraded shares of Senseonics from a “hold” rating to a “sell” rating in a report on Wednesday, January 30th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. Senseonics currently has an average rating of “Hold” and a consensus price target of $6.25.

Senseonics (NYSEAMERICAN:SENS) last issued its earnings results on Thursday, May 9th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.05). The company had revenue of $3.42 million for the quarter, compared to the consensus estimate of $4.05 million.

Institutional investors have recently modified their holdings of the business. Commonwealth Equity Services LLC bought a new stake in shares of Senseonics during the 1st quarter valued at $27,000. Amalgamated Bank bought a new position in Senseonics in the 4th quarter worth about $28,000. Creative Planning bought a new position in Senseonics in the 1st quarter worth about $34,000. First Allied Advisory Services Inc. bought a new position in Senseonics in the 4th quarter worth about $35,000. Finally, Mogy Joel R Investment Counsel Inc. bought a new position in Senseonics in the 1st quarter worth about $37,000. 30.66% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Senseonics (SENS) Trading Down 5.7%” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at

About Senseonics (NYSEAMERICAN:SENS)

Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.

Read More: Trading Ex-Dividend Strategy

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with's FREE daily email newsletter.